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Summary 
Emerging pollutants are thought to be responsible for the most 
significant share of environmental, human health and economic risk. 
Although the universe of chemical pollutants is enormous, we only 
monitor and have studied a minor fraction. 
The study of the fate of the emerging pollutants and their 
transformation products in wastewater-treatment plants (WWTP) is 
of paramount importance, since it can provide valuable information 
on the human consumption of various drugs. Sewage epidiomiology 
is the new field that was develloped for the estimation of illicit drug 
use based on measurements of urinary excreted illicit drugs and their 
metabolites in untreated wastewater. Within this approach, human 
metabolic excretion products resulting from drug consumption are 
rapidly collected and pooled by the sewage systems, providing 
valuable evidence of the amount and type of drug consumed by a 
population. 
The main objective of this research is the contribution to the 
current knowledge on the actual burden of micropollutants on the 
environment and on the effect they have on the human health.  
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Introduction 
Urban wastewaters contain a large number of substances, 
including several human metabolites. Besides serving to control the 
types and the amounts of pollutants discharged into the 
environment, the analysis of micropollutants present in wastewater 
can also provide valuable information about patterns of human use of 
these substances. Human metabolic excretion products, both parent 
compounds and TPs, resulting from drug use are rapidly collected 
and pooled by the sewage systems. Analyzing these substances in the 
influent wastewaters could provide evidence of the amount and type 
of drug used by a population (Daughton, 2001).  
The official ways to obtain figures about the use of drugs are 
surveys integrated with medical records and drug production data. 
These tools give a useful general picture of drugs, but estimates of 
use rates and drug use prevalence may be inaccurate and have also 
several limitations. One of the main disadvantages is the inclusion of 
substantial time lags that negatively impact the reliability, validity 
and utility of such data (van Nuijs et al., 2011). In the case of illicit 
drugs the biased selection of the population that is needed may lead 
to an underestimation of the use rates and also to incorrect estimates 
since most of the information is obtained from the users (Castiglioni 
et al., 2013). There is a recent option to get this information based on 
data obtained from influent wastewater, which can be used to back-
calculate the mass loads of the parent drugs and/or metabolites. 
These loads allow the estimation of its use (knowledge of the drug 
metabolism and excretion patterns is required). Including served 
population by the corresponding wastewater treatment plant 
(WWTP) in the equation, it is possible to make a comparison with 
results from different locations (van Nuijs et al., 2011). Several 
studies have already used these methodologies to back calculate drug 
use (Bones et al., 2007, Zuccato et al., 2008, Postigo et al., 2008, Ort et 
al., 2014, Been et al., 2014, United Nations, 2012). One of the main 
advantages of calculating the loads by analyzing the influent 
wastewaters is that it allows a rapid detection of changes in the 
patterns of illicit drugs as well as the facility for comparing data. 
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Greece is amongst the most affected countries by the severe 
economic crisis plaguing Europe since 2008. The inability to continue 
financing its public debt caused significant cuts in the public sector, 
including healthcare. In 2010, the Greek government requested a 
loan from the EU, which was the first request for a resave due to the 
impossibility of keeping limiting the public debt. The effects of this 
crisis in Greece directly affect its population, with growing 
unemployment rates (up to 30%), a substantial decline in per capita 
income and a significant increase in poverty. Another consequence 
has been a great decrease in public spending for health, which is now 
less than any of the other pre-2004 European Union members 
(Kentikelenis et al., 2014, Stuckler & Basu, 2013). Some studies point 
to a change in the use of drugs, especially since in 2012 the Greek 
government surpassed the Troika’s demands for cuts in drug 
spending (Kentikelenis et al., 2014, European Commission 2012, 
European Commission 2013). These studies also suggest an 
increment in the use of some illicit drugs. However, there are not 
extensive studies using chemical data to support and quantify these 
hypotheses so far. The analysis of wastewater offers great 
possibilities for the obtaining of solid data to confirm and expand the 
knowledge in this regard. 
The objective of this work is to use the tools offered by 
analytical chemistry and sewage epidemiology and relate the use of 
various classes of licit and illicit drugs with the effects of the 
economic crisis. Contradictory factors, like severe cuts in expenditure 
for drugs and increase of mental illnesses due to the stress associated 
to the crisis, may affect the licit drug use in the population. Moreover, 
the use of illicit drugs in the community cannot be predicted. This 
study aims to provide information on changes in use patterns of licit 
and illicit drugs during the last 5 years (2010 – 2014) and relate this 
data to social parameters such as the unemployment rate or the 
decrease in the public health investments through the evaluation of 
the obtained use trends of the different studied substances. It should 
be emphasized that the studied WWTP serves half the population of 
Greece and it is located where the effects of the crisis are more 
noticeable. 
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Study of licit and illicit drugs, quantified through sewage-
based epidemiology 
In order to achieve the aforementioned objective, 
antidepressants, anxiolytics, antipsychotics, antibiotics, 
antiepileptics, analgesics, NSAIDs, diuretics, antihypertensives, 
antiulcers and steroids (a representative sample of the licit drugs 
used in a modern society) were considered, as well as the main illicit 
drugs and their metabolites. The concentrations of these substances 
in influents were monitored from 2010 to 2014 in Athens. Applying 
methods of back-calculation to each of the substances, daily use 
values were estimated and results were discussed and correlated 
with the severe socioeconomic changes.  
 
Samples 
All the influent wastewater samples considered in this study 
were collected from the WWTP of Athens (Greece) during five 
sampling campaigns conducted from 2010 to 2014.  
The WWTP of Athens is designed with primary sedimentation, 
activated sludge process with biological nitrogen and phosphorus 
removal and secondary sedimentation. The average sewage flow for 
the periods of study was 720,000 m3 day-1 for a typical dry day. For 
the load calculations the specific day flow has been used. As for the 
travel distances of wastewater in the sewer, the closest connected 
household is 0.5 km and the most remote is 30 km away. The 
residential population connected to the WWTP based on official 
census excluding the commuters is 3,700,000 and the number of 
people estimated based on number of house connections is 
4,562,500. This WWTP has a design capacity to serve a population 
equivalent of 5,200,000, being by far the largest of Greece and one of 
the largest in the world. For the drug use estimations, we used the 
census value for the residential population. 
In each campaign influent wastewater samples (24-hour 
composite flow proportional samples) were collected during 7 
consecutive days from 5/12 to 11/12 in 2010, on 8 days from 3/4 to 
10/4 in 2011, on 8 days from 2/4 to 9/4 in 2012, on 11 consecutive 
days from 6/3 to 16/3 in 2013 and on 8 days from 11/3 to 18/3 in 
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2014. This allows investigation of drug use trends throughout the 
week and over the course of the study period. All wastewater 
samples were collected in pre-cleaned high-density polyethylene 
(HDPE) bottles. Untreated and treated wastewater samples were 
immediately filtered with glass fiber filters (pore size 0.7 μm) after 
arrival at the laboratory. Samples were acidified with a 1 M HCl 
solution to pH 2.5 ± 0.10 and stored in the dark at 4 °C until analysis. 
 
Analysis and Evaluation of the data 
The analytical method for the determination of 148 substances 
is based on solid phase extraction and further analysis by LC-MS/MS, 
according to Thomaidis et al. (2015). The approach for the estimation 
of the drug usage can also be retrieved from the publication 
(Thomaidis et al. 2015). 
 
Results for licit and illicit drugs 
Pharmaceuticals 
Results showed high concentrations of pharmaceuticals in the 
influent wastewater samples in all five sampling campaigns. Up to 
128 out of the 148 target drugs and related metabolites were 
detected, in concentrations in some cases above 200 µg L-1. In figure 
1, the variations in use in terms of mean loads (g day-1) in the 
analyzed influent samples are presented for the most relevant 
compounds.  
 
1a 1b  
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Figure 1. Estimated use (mean values, g day-1) for selected pharmaceuticals. 
  
1c 1d 
1e 1f 
1g  
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Different patterns were observed for the various therapeutic 
families of monitored compounds between the different sampling 
periods. While the use of some substances increased significantly, 
such as benzodiazepines and antidepressants, the use of others 
decreases considerably (e.g. NSAIDs). Significant differences were 
also observed in the used amounts of some compounds within the 
same therapeutic family. 
Variations in the use of benzodiazepines anxiolytics and 
various types of antidepressants are shown in Figure 1a. A 
pronounced increase in the overall use of both antidepressants 
(TeCAs, SSRIs and SNRIs) and benzodiazepines was observed (from 
~36,000 to ~500,000 doses day-1 for the substances), with a 
remarkable increase for all the studied compounds of these 
therapeutic families. The oxazepam and citalopram cases are 
remarkable, with high increase during the sampling period reaching 
use rates of 203,638 and 116,416 doses day-1 (3055 and 2328 g day-
1), respectively. The observed increase in use of paroxetine, an 
antidepressant widely used (reaching values up to 96,833 doses day-1 
(1,937 g day-1)), is also noteworthy. For compounds of these 
therapeutic families for which data on excretion and increased 
bioavailability were not available (e.g. sertraline/norsetraline, 
amitriptyline, bromazepam or temazepam), an increase of the same 
magnitude in the concentrations detected in the influent wastewater 
samples was also observed. The detected levels for the studied 
antipsychotics (e.g. clozapine, olanzapine) in the influent 
wastewaters followed the trend of the other psychiatric drugs and 
showed a marked increase every year from 2010 to 2014.  
Other families of drugs with an increase in use during the 
period studied were antihypertensives (Figure 1b), highlighting the 
large increase in the use of valsartan. The average use of this 
compound increased from 25,988 doses day-1 (8,316 g day-1) in 2011 
to over 625,000 doses day-1 (>200 kg day-1) in 2013, with a slight 
decrease in 2014. Another antihypertensive drug with a pronounced 
increase was propranolol. A similar but less pronounced pattern was 
found for the anti-ulcer drugs. A significant increase in use of 
ranitidine during the study period was observed, from 7,607 doses 
day-1 (1,141 g day-1) (2011) to values above 20,000 doses day-1 
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(3,040 g day-1) (2013, 2014) (Figure 1c). The family of antiepileptics 
showed a constant increase in overall use. However, important 
differences in the use of drugs within this family were observed. 
While a significant decrease in use was observed for carbamazepine 
(which is one of the most widely prescribed and very important 
compound for the treatment of epilepsy, neuralgia and some 
psychiatric diseases, such bipolar affective disorder), an increased 
even more pronounced was determined for valproic acid (from 
11,494 doses day-1 (22,988 g day-1) in 2010 to 36,761 doses day-1 
(73,521 g day-1) in 2014, Figure 1d), a compound which has very 
similar applications. A significant increase was also observed for 
lamotrigine, reaching 15,180 doses day-1 (3036 g day-1) in 2014.  
The use of antibiotics (Figure 1e), which are among the most 
frequently prescribed drugs for humans in modern medicine, showed 
a slight decrease between the different periods studied as it can be 
observed in the Sum graphic. Significant decreases were observed in 
the use of the macrolide clarithromycin (from 4,019 doses day-1 
(2010 g day-1 in 2011 to 624 doses day-1 (312 g day-1) in 2014) and 
for the fluoroquinolone ciprofloxacin (from 4,827 doses day-1 (2413 g 
day-1) in 2011 to 3,558 doses day-1 (1,779 g day-1) in 2014), two 
widely prescribed antimicrobials. These compounds were detected at 
the highest concentrations in the present study, in comparison with 
other investigations conducted in influent wastewater in other 
countries (Guerra, 2014). To a lesser extent, reduction in the use of 
norfloxacin, sulfamethoxazole or trimethoprim were also observed. 
An exception can be found in the significantly higher use of 
metronidazole throughout the sampling period (from 1,784 doses 
day-1 (892 g day-1) in 2011 to 3,834 doses day-1 (1,917 g day-1) in 
2014).   
Non-steroidal anti-inflammatory drugs (NSAIDs) were the 
substances detected at highest concentrations and with the highest 
use rates (Figure 1f). These drugs, which are used for treatment of 
acute pain and inflammation, are administered both orally and 
topically and are available as prescription and over-the-counter 
(non-prescription) (Jelic et al., 2011). The overall use of these drugs 
remained stable with no significant differences except for mefenamic 
acid, for which a high decrease was observed in its use. For 
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antilipidemics and the diuretic hydrochlorthiazide, no significant 
variations could be derived (Figure 1g). Gemfibrozil showed a high 
variation of its use, with a significant decrease in 2012, and 
significant increase in 2014. A significant increase in 2014 was 
observed for hydrochlorthiazide, as well, but not in 2013. In general, 
hydrochlorthiazide is associated with antihypertensive substances 
like valsartan and other sartans and angiotensin-converting enzyme 
(ACE) inhibitors (like Captopril, Ramipril and others not included in 
this study). Therefore, sound conclusions for this compound could 
not be derived.   
 
Illicit drugs 
Drugs of abuse in general showed a clear pattern of use during 
the week. For some of these substances a sharp increase in use 
during the weekend was detected in all the monitored periods. The 
highest concentrations were detected in samples of Saturdays, 
Sundays and, in some cases, of Mondays.  
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Figure 2.  Daily use (g day-1) of drugs of abuse through the five years 
investigation (2010-2014). 
 
Figures 2a, 2b and 2c show the graphs of daily use (seven days 
for five different sampling campaigns) for cocaine, ecstasy and 
amphetamine, respectively. These substances are representative 
cases of the pattern mentioned above. In the case of ecstasy, changes 
in daily use were very strong, with use rates up to ten times higher 
than the ones detected on weekdays, suggesting that the use of this 
substance is practically restricted to the eve of non-working days. 
The weekly variation for amphetamine in the sampling period of 
2010 is very similar to the ecstasy trends. However, variations 
throughout the week were not noticeable in the other four sampling 
campaigns. This is maybe related to the fact that the recreational use 
of this drug has decreased and the amounts detected correspond to 
its additional use as therapeutic drug in hospitals, since this 
substance is widely used in the treatment of some diseases, such as 
attention deficit hyperactivity disorder (ADHD) or narcolepsy. A 
strong trend was also clearly observed for cocaine, although the 
differences between weekends and weekdays are not as high as in 
the case of ecstasy. Cocaine use seems to be much more widespread, 
with higher g day-1 values. In this case, significant use during 
weekdays was also detected. Regarding this substance, noteworthy 
were the high values observed in the samples corresponding to 
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Mondays, reflecting a very high intake of this substance also on 
Sundays.  
By contrast, other substances exhibited a relatively more 
constant use throughout the week. An example of this pattern can be 
found for heroin and methadone (Figure 2d and 2e, respectively), for 
which the use remained constant and did not increase significantly 
during the weekends. Another example of this pattern was observed 
for methamphetamine (Figure 2f). This is a so called “street” drug, 
and its pattern was clearly different than that of recreational drugs 
(e.g. cocaine, ecstasy) and whose use strongly increases during 
weekends. The “street” drugs of abuse, like heroin and 
methamphetamine (known also as sisa in Greece), are more related 
to marginal conducts, and their use was relatively constant 
throughout the week.  
The case of cannabis use is noteworthy (Figure 2g), since this 
drug somehow perceived as a recreational one. Although some 
studies showed an increase in its use during the weekends (Viana et 
al., 2011), most of them did not report weekly patterns (Ort et al., 
2014, Thomas et al., 2012). In the present study, a correlation 
between use and the specific day of the week was not clearly 
observed. Use of THC was not constant but varied significantly 
without following a specific pattern. An exception was the results for 
Friday and Saturday in the monitoring campaign of 2013. The high 
values reported in those days can be distorted by the proximity of the 
Carnival of Athens, which may be strongly related to a higher use of 
this substance. This suggests that the pattern of use of illicit drugs 
could vary considerably from one country (or city) to another (Ort et 
al., 2014, European Union, 2013). 
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Table 1. Weekly drug use and percentage of population under use per year. 
Compound 
December 2010 April 2011 April 2012 March 2013 March 2014 
Weekly 
use 
(Kg) 
Popula-
tion 
under 
use* 
(%) 
Weekly 
use 
(Kg) 
Popula-
tion 
under 
use* 
(%) 
Weekly 
use 
(Kg) 
Popula-
tion 
under 
use* 
(%) 
Weekly 
use 
(Kg) 
Popula-
tion 
under 
use* 
(%) 
Weekly 
use 
(Kg) 
Popula-
tion 
under 
use* 
(%) 
Cocaine 3.31 0.12 3.42 0.12 3.31 0.12 3.70 0.13 4.83 0.17 
Heroin 6.24 0.74 7.35 0.87 3.92 0.47 6.22 0.74 9.18 1.09 
Ampheta-
mine 
2.73 0.33 1.39 0.17 0.44 0.053 1.37 0.16 1.44 0.17 
Meth-
ampheta-
mine 
0.14 0.017 0.14 0.017 0.28 0.033 0.29 0.034 0.32 0.038 
MDMA 
(Ecstasy) 
0.039 0.0014 0.043 0.0015 0.063 0.0023 0.13 0.0048 0.17 0.0061 
THC 
(cannabis) 
- - 211.6 6.0 234.4 6.7 382.9 10.9 265.5 7.59 
Metha-
done 
0.14 - 0.24 - 0.51 - 0.82 - 0.97 - 
Codeine 1.04 - 1.21 - 1.37 - 2.03 - 2.03 - 
*based on the average dose and for a population of 3,700,000 people. 
 
Regarding the variation with respect to the different sampling 
periods, different patterns were observed. In addition to Figure 2, the 
weekly use for each substance is summarized in Table 1, as well as 
the estimated population under use, based on the average dose and 
for a population of 3,700,000 people. Cocaine use amongst the five 
sampling periods showed no significant variations. The use of this 
substance remained about 3.3 kg week-1 (except in 2014, where the 
use increased to 4.83 kg week-1). However, amphetamine use (2.73 
kg week-1 in 2010) declined significantly in 2011 (1.39 kg week-1) 
and 2012 (0.44 kg week-1) with a slight increase in 2013, which 
remained in 2014. On the contrary, ecstasy experienced a significant 
increase. The estimated use of this substance in 2014 was 0.17 kg 
week-1, while the 2010 estimated use being only 0.039 kg week-1. Use 
of cannabis increased from 211.6 kg week-1 in 2011 to 265.5 kg week-
1 in 2014. The high estimated use in 2013, 382.9 kg week-1, can be 
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related to the proximity of the Carnival of Athens, as explained 
before.  
Significant changes were detected in methamphetamine use 
associated with the so called "sisa", a newly introduced form of the 
drug related to marginal conducts. The weekly estimated use of this 
substance increased from 0.14 kg week-1 in 2010 and 2011 to values 
above 0.28 kg week-1 in 2012 and onwards. Methadone use also 
experienced a significant increase during these years, from 0.14 kg 
week-1 in 2010 to 0.97 kg week-1 in 2014. Heroin abuse has changed 
during the study period (3.9 – 9.2 kg week-1) without a defined trend. 
The amount of morphine due to codeine use has been taken into 
account for the calculation of heroin use. However, the therapeutic 
use of morphine was not taken into account due to the absence of 
data and the unwillingness of the Greek state to provide this data. 
The therapeutic morphine may represent a significant portion of the 
total amount of this substance in wastewater. This may lead to an 
overestimation of the heroin use. This is in agreement with the fact 
that the percentage of people under use of this substance (0.74 %) is 
significantly higher than the one published in the European Drug 
Report 2013 (0.25 – 0.3%). One solution to this problem would be to 
perform the back-calculation from a minor metabolite (6-MAM), but 
concentrations obtained for this compound are below the limit of 
quantitation in most cases. Therefore, heroin use data may be 
overestimated and the detected changes in use may also be a 
consequence of variations in the use of therapeutic morphine. It is 
noteworthy that codeine use was also increased in 2013 and 2014 
(Table 1). However, since use data could not be derived from the 
relevant ministries, no sound conclusions can be drawn about the use 
of heroin from these data. 
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Occurrence of new designer drugs of abuse and their 
transformation products 
The aim of this study is a comprehensive quantitative target 
screening of emerging pollutants in environmental samples, which 
involves a generic sample preparation, a UPLC-QTOF-MS/MS method 
and post-acquisition evaluation of the data. An in-house database 
was built with information of retention time, MS and MS/MS ions for 
2327 compounds, including pesticides, pharmaceuticals, drugs of 
abuse, industrial chemicals, doping compounds, as well as 
metabolites and transformation products. Out of this database, 745 
new designer drugs, drugs of abuse and psychoactive 
pharmaceuticals (PP) were examined more thoroughly. 
 
Samples 
Influent and effluent wastewater samples were collected from 
the WWTP of Athens (Greece) during two sampling campaigns 
conducted on 2014 and 2015.  
In each campaign influent and effluent wastewater samples 
(24-hour composite flow proportional samples) were collected 
during 7 consecutive days from 11/3 to 18/3 in 2014 and from 4/3 
to 11/3 in 2015. Moreover, 12 influent 2-hour composite flow 
proportional samples were collected for 2 days (Tues. 12/3 & Sat. 
15/3/2014). 
 This allows investigation of drug use trends throughout the 
week and over a weekday and weekend. All wastewater samples 
were collected in pre-cleaned high-density polyethylene (HDPE) 
bottles. Untreated and treated wastewater samples were 
immediately filtered with glass fiber filters (pore size 0.7 μm) after 
arrival at the laboratory. Samples were stored in the dark at 4 °C until 
analysis. 
 
Analysis & Evaluation of the data 
 Optimization was performed in order to minimize false 
negative results and a validation protocol is proposed in order to 
evaluate the performance criteria of the HRMS method. The samples 
were analyzed and evaluated with sophisticated software (Bletsou et 
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al., 2015). Identification points were attributed to each analyte and 
quantitation was also carried out. 
 
Results 
The results obtained revealed that analytes from different 
categories, such as NPSs, alkaloids, DoAs, central nervous system 
(CNS) pharmaceuticals and metabolites of those compounds, were 
present in the wastewater samples in the range of few ng/L and μg/L 
levels. Moreover, intra-day and intra-week variation was estimated 
and time profiles were derived for most of the compounds. 183 
compounds were detected at least once in influent wastewaters and 
163 in effluent wastewaters. The detection of NPSs and DoAs in 
wastewater can provide valuable information on the use of these 
substances in the community. 
Some compounds are present in both studies and are 
presented in more detail in the sewage-based epidemiology study, 
where more data are available. The advantage of this HRMS method 
is the possibility for post-acquisition evaluation of the data and the 
retrospective analysis. In that sense, compounds that are reported for 
the first time, or newly released compounds will be the focus of that 
second study. 
Stimulants – Amphetamines 
Among others, 29 stimulants in total (Table 2) were detected in 
wastewater samples in concentration levels from 0.0013 μg/L 
(ethylamphetamine) – 3.62 μg/L (Phenelzine), in influent 
wastewaters. 
 
Table 2. Stimulants and amphetamines detected in wastewater samples 
  
CAS 
Number 
Influent 
wastewater 
Identification 
Points 
Effluent 
wastewater 
Identification 
Points 
1 Cocaine (COC) 50-36-2 5 n.d. 
2 Benzoylecgonine (BECG) 519-09-5 ≥5 2 
3 Ecgonine methyl ester (EME) 
7143-09-
01 
2 n.d. 
4 Amphetamine 300-62-9 ≥5 n.d. 
5 Methamphetamine (MA) 537-46-2 2.5 n.d. 
6 Dimethylamphetamine 1009-69- 2.5 2.5 
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4 
7 Ethylamphetamine 457-87-4 2 2.5 
8 
3,4-
methylenedioxyamphetamine 
(MDA) 
4764-17-
4 
≥5 2 
9 
3,4-methylenedioxy-N-
methylamphetamine 
(MDMA) 
42542-
10-9 
2 2 
10 
PMMA (para-Methoxy-N-
methylamphetamine) 
3398-68-
3 
5 5 
11 
Metaraminol (3,β-
dihydroxyamphetamine) 
337376-
15-5 
2.5 n.d. 
12 
Pholedrine (p-hydroxy-
methylamphetamine) 
6114-26-
7 
n.d. 2.5 
13 4-methyl-2-hexanamine 105-41-9 2 2 
14 Mephentermine 100-92-5 2 2.5 
15 Phenelzine 51-71-8 2 2.5 
16 Pyrovalerone 
3563-49-
3 
n.d. 2.5 
17 Phendimetrazine 
17140-
98-6 
2 2 
18 Midodrine 
133163-
28-7 
2 2.5 
19 Heptaminol 372-66-7 2.5 2.5 
20 
Cathine/ 
norpseudoephedrine 
492-39-7 2.5 2.5 
21 Nikethamide 59-26-7 n.d. 2.5 
22 Pemoline 
2152-34-
3 
2 n.d. 
23 Aminorex 
2207-50-
3 
2 2 
24 Dimefline 
1165-48-
6 
n.d. 2.5 
25 Ethamivan 304-84-7 n.d. ≥5 
26 
TMA 
(trimethoxyamphtamine) 
1082-23-
1 
2 2 
27 
3,4-DMA 
(dimethoxyamphtamine) 
120-26-3 2 2 
28 
4-Methyl-
pyrrolidinopropiophenone 
(MPPP) 
28117-
80-8 
2 2 
29 
2 C-D (2,5-dimethoxy-4-
methylphenethylamine) 
24333-
19-5 
2 2.5 
 
Apart from the well-known amphetamine-derivatives, such as 
AMP, MA, MDA, MDMA and MDEA, some compounds are reported for 
the first time in the same concentration levels in wastewater 
samples; such as 2,5-dimethoxy-4-methylphenethylamine (2C-D), 
dimethoxyamphtamine, trimethoxyamphtamine, ethylamphetamine, 
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dimethylamphetamine, para-Methoxy-N-methylamphetamine 
(PMMA), 4'-Methyl-α-pyrrolidinopropiophenone (MPPP), cathine, 
aminorex, phendimetrazine, mephentermine, midodrine, heptaminol, 
bemegride and pemoline. 
 
Opiates -Opioids 
5 compounds were detected in influent wastewaters, 
morphine, normorphine, methadone, codeine & EDDP, while 2 more 
metabolites were detected in effluent wastewaters, norcodeine and 
hydrocodone. This is a proof of the degradation processes that take 
place during the wastewater treatment procedure. 
 
More drugs 
From the sympathomimetics drugs, 9 were detected, among 
them ephedrine, norephedirne and etafedrine, as well as 
metanephrine, phenylephrine, apophedrin, isoetharine, 
methoxamine and nylidrin. 
Antidepressant drugs from different categories, such as SSRIs 
(selective serotonin reuptake inhibitors), SNRIs (serotonin-
norepinephrine reuptake inhibitors), TCAs (tricyclic 
antidepressants) and MAOIs (monoamine oxidase inhibitors) were 
also present in the samples. 
Moreover, benzodiazepines, with oxazepam as a characteristic 
example were present in the samples, following the same trend 
during the week with that presented in the first study. Antiepileptics, 
barbiturates, anesthetics and antipsychotics (clozapine) were also 
detected in the samples. 
 
Intra-day and intra-week variation of parent compounds and 
their metabolites 
 
The intra-day concentration profile of parent and metabolites 
can be used to provide additional evidence for the identification the 
metabolites. Figure 3 shows this for clarithromycin and two related 
metabolites, N-desmethyl clarithromycin and hydroxyclarithromycin. 
As the concentration in influent wastewater was measured every two 
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hours, it can be observed that the profiles are identical for the 
metabolites and for clarithromycin.  
 
Figure 3. MS/MS spectra and intra-day concentration profiles of clarithromycin 
and its metabolites N-desmethyl clarithromycin and hydroxyclarithromycin. 
 
This procedure was also used in the case of venlafaxine and its 
two metabolites N-desmethyl venlafaxine and O-desmethyl 
venlafaxine, as it is shown in Figure 4. An excellent interrelation in 
the intra-day profiles among parent/metabolites was observed.  A 
good intra-day interrelation between the two confirmed metabolites 
cotinine and hydroxycotinine (Figure 5) was also observed, but these 
profiles did not match the profile of the parent compound, nicotine, 
well. This indicates that this new strategy can provide valuable 
additional evidences for the identification, but the results should be 
interpreted with caution. The absence of interrelation does not imply 
a false positive.   
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Figure 4. Intra-day concentration profiles of venlafaxine and related metabolites 
 
 
Figure 5. Intra-day concentration profiles of nicotine and related metabolites. 
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When comparing the intra-day trends between a week day and 
Saturday (weekend), there are interesting facts, concerning the use of 
some compounds during the weekdays and the weekends. 
 
 
Figure 6. Intra-day concentration profiles of PMMA and etafedrine during a 
weekday (12-Mar) and Weekend (Sat. 15-Mar) 
 
In Figure 6, we can observe that the peak concentration for PMMA 
and etafedrine, both stimulants, is on the weekday at 8 am, whereas 
on Saturday, the maximum concentration is observed at midday. 
 
Similar conclusions were reached from the comparison of the 
intra-week concentration profiles among parent compounds and 
related metabolites. Very similar profiles were observed for the 
aforementioned metabolites of clarithromycin and venlafaxine and 
their corresponding parent compounds during 7 consecutive days 
(Figure 7a and 7b). Also good interrelations were found for the 
metabolites ranitidine-S-oxide and tramadol-N-oxide with their 
parent compounds (data not shown).  
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Figure 7. Intra-week concentration profiles of (a) clarithromycin and related 
metabolites and (b) venlafaxine and related metabolites 
 
However there are cases, where no significant trend is 
observed among the days of the week, but it applies the same for the 
parent compounds and the metabolites, as in the case of 
carbamazepine (Figure 8). 
 
 
Figure 8. Intra-week concentration profiles of carbamazepine and related 
metabolites  
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Increased values were observed during the weekend, or on 
Friday for some analytes (Figure 9), such as for 2 C-D, a psychedelic 
drug, acting as a stimulant and a drug which serves as a supporting 
measure in treating depressant overdose, bemegride. 
  
Figure 9. Intra-week loads profiles of (a)2 C-D and (b) bemegride  
 
Monitor use of parent compounds and evaluation of 
metabolites as biomarkers 
 
Population size and dynamics are important parameters in 
many human activities, including material-flow analysis in different 
environmental matrices and the per capita contributions of different 
pollutants to the environment “pollutant load per capita”. This is 
particularly relevant for the “wastewater-based epidemiology” 
approach, which involves analysis of urban wastewater for the 
combined excretion products of different substances to track human 
habits and lifestyle. This approach was originally developed for the 
estimation of illicit drug consumption through wastewater analysis 
but can be extended to other applications, such as alcohol and 
nicotine. The rationale for this approach is based on the fact that 
almost everything we consume is excreted unchanged and/or as a 
mixture of metabolites in our urine and feces and ultimately ends up 
in the sewage network. Thus, the concentrations of metabolic 
residues in raw municipal wastewater can reflect the collective 
consumption of a substance in a community (Senta et al., 2015). 
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The use of caffeine, nicotine and some major metabolites was 
investigated by wastewater analysis and their suitability was tested 
as qualitative and quantitative biomarkers for assessing population 
health status. 
These compounds were found widely at the mg/L level and 
mass loads were calculated by multiplying concentrations by the 
wastewater daily flow rate and normalized to the population served 
for the plant. 
The criterion for selecting metabolites is the percentage of 
excretion of each metabolite. Thus for caffeine, paraxanthine, 
theophylline and theobromine were examined. The outcome is that 
in Athens, the consumption of coffee reaches 6.5 g caffeine /day/ 
1000 inhibitants, whereas the upper limit is <200 mg/day, according 
to EFSA guideline. In Figure 10, the intra-day and intra-week trend of 
the consumption of caffeine is presented. 
 
Figure 10. (a)Intra-week trend and (b) intra-day trend for a weekday (12-Mar) 
and weekend (Sat. 15-Mar) of caffeine 
 
For nicotine, we selected two main metabolites excreted in 
urine: cotinine (30%) and 3-hydroxycotinine (44%). The profiles of 
cotinine and 3-hydroxicotinine in wastewater were very similar and 
reflected their human excretion profiles. From the mass loading of 
the metabolites and according to excretion rates, we come up to 
nicotine equivalents and by taking into consideration the mean 
content of nicotine absorbed from one cigarette, we can exclude the 
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number of cigarettes smoked per day in Athens, that reach the 
number of 13.6 million. If we count for the average number of 
cigarettes smoked per smoker (21.4 cigarettes per day) 
(http://livingingreece.gr/2010/05/31/smoking-greece/), we can 
conclude in the number of 640,000 smokers in Athens.  
 
Conclusions and Future Research 
The sewage epidemiology application for illicit drug 
consumption monitoring could be used prospectively in a multi-
disciplinary approach. It can give valuable information on using 
updated drug profile analyses to rapidly identify emerging hot spots 
of drug abuse. It can be of great help to test in real time the efficacy of 
different counter-measures such as prevention through education, 
enforcement, and global concerted actions against illicit drug 
consumption. Moreover it can cross-validate population surveys 
versus wastewater monitoring programs and it can assess the actual 
amount of illegal money involved in drug trafficking. If applied to 
other public health issues, this approach could potentially extract 
useful epidemiological data from qualitative and quantitative 
profiling of biological indicators entering the sewage system and 
might reopen the debate on what type of surveillance approaches are 
ethically and politically acceptable (van Nuijs et al., 2011). 
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